echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > How to deal with the California variant of SARS-CoV-2?

    How to deal with the California variant of SARS-CoV-2?

    • Last Update: 2021-04-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Vir Biotech today announced a new preclinical study to prove that the company's research SARS-CoV-2 monoclonal antibody VIR-7831 can maintain its neutralizing effect.
    The results of the study also showed that the L452R mutation of SARS-CoV-2 reduced the neutralizing activity of the plasma of vaccinators and convalescent donors.
    The data has been published on bioRxiv on April 1, 2021, and has been submitted to a peer-reviewed journal.

    In this new study, Vir and Washington University researchers reported on the rapid and exponential growth of the California variant in all 50 states in the United States and 29 other countries around the world, and described the effects of its three mutations: S13I, W152C and L452R.

    Data from 43 vaccinated donors and 9 convalescent donors showed that in the pseudotyped virus system, the S13I, W152C, and L452R mutations reduced the neutralization ability of plasma by three to six times.
    The researchers also observed that VIR-7831, which targets a non-receptor binding motif (RBM) epitope, is not affected by the L452R mutation.

    The researchers also observed that VIR-7831, which targets a non-receptor binding motif (RBM) epitope, is not affected by the L452R mutation.
    The researchers also observed that VIR-7831, which targets a non-receptor binding motif (RBM) epitope, is not affected by the L452R mutation.

    Dr.
    David Veesler, associate professor of biochemistry at the University of Washington, said: “It is worrying that this variant has rapidly increased in frequency in California and neighboring states and has the ability to confer a certain degree of resistance to vaccines and antibody therapies.
    This variant The sensitivity to plasma antibodies is reduced.
    Together, these data indicate that if we are to fight current and expected future variants, there is an urgent need for monoclonal antibodies that target the constant region of the spike protein.
    "

     

    Original source:

    Original source:

    href="" target="_blank" rel="noopener">

    leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.